Aktuellt
SENASTE
Redeye views the Q3 report from Moberg Pharma as very much in line with what was expected. The national approvals have come in as indicated by the company, and even though sales will not begin in most countries until 2026e, the signal is positive as it indicates that the progress is according to the plan. We maintain our Base case of SEK 19 per share (Based on further dilution in May 2024e due to warrants)
LÄS MER
